Prognostic role of lymph node regression in patients with esophageal cancer undergoing neoadjuvant therapy
- Pingrun Chen 1, Maojia Chen 2, Yijie Bu 3, Guowei Che 4, Chao Cheng 3, Yan Wang 3
- Pingrun Chen 1, Maojia Chen 2, Yijie Bu 3
- 1Department of Gastroenterology and Hepatology, West China Hospital, Sichuan University, Chengdu, China.
- 2Animal Experiment Center, West China Hospital, Sichuan University, Chengdu, China.
- 3Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, China.
- 4Department of Thoracic Surgery/Lung Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
- 0Department of Gastroenterology and Hepatology, West China Hospital, Sichuan University, Chengdu, China.
Related Experiment Videos
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Lymph node regression (LNR) and N downstaging are reliable prognostic factors for esophageal cancer patients undergoing neoadjuvant therapy. Complete LNR and N downstaging significantly improve survival outcomes.
Area Of Science
- Oncology
- Gastroenterology
- Surgical Oncology
Background
- Neoadjuvant therapy is a standard treatment for esophageal cancer.
- Accurate prognostic markers are crucial for tailoring treatment strategies.
- Lymph node status is a key determinant of patient survival in esophageal cancer.
Purpose Of The Study
- To evaluate the prognostic significance of lymph node regression (LNR) status, including LNR grade (LNRG) and N downstaging.
- To determine the impact of LNR and N downstaging on survival outcomes in esophageal cancer patients receiving neoadjuvant therapy.
Main Methods
- A systematic literature search was conducted across multiple databases up to March 25, 2024.
- Meta-analysis of 14 retrospective studies involving 3,212 patients.
- Outcomes analyzed included overall survival (OS), disease-free survival (DFS), and cancer-specific survival (CSS).
Main Results
- Complete LNR was associated with significantly improved OS (HR=0.47) and DFS (HR=0.42).
- N downstaging demonstrated a significant improvement in OS (HR=0.40) and CSS (HR=0.27).
- Subgroup analyses by neoadjuvant therapy type and pathological classification confirmed these findings.
Conclusions
- Lymph node regression (LNR) serves as a robust prognostic indicator in esophageal cancer patients treated with neoadjuvant therapy.
- Achieving complete LNR and N downstaging are linked to superior survival.
- These findings support the integration of LNR and N downstaging into routine prognostic assessments.
Related Experiment Videos
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.

